A5032112170- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Immunodeficiency and Autoimmune Disorders
- Pregnancy and Medication Impact
- Reproductive System and Pregnancy
- Biosimilars and Bioanalytical Methods
- Adolescent and Pediatric Healthcare
- Liver Diseases and Immunity
- Diagnosis and treatment of tuberculosis
- Chronic Lymphocytic Leukemia Research
- Health Systems, Economic Evaluations, Quality of Life
- Autoimmune and Inflammatory Disorders
- Helicobacter pylori-related gastroenterology studies
- Childhood Cancer Survivors' Quality of Life
- Hidradenitis Suppurativa and Treatments
- Liver Disease Diagnosis and Treatment
- Diverticular Disease and Complications
- Pharmaceutical Economics and Policy
- Tuberculosis Research and Epidemiology
- Clostridium difficile and Clostridium perfringens research
- Pancreatitis Pathology and Treatment
- Liver Disease and Transplantation
- Renal Diseases and Glomerulopathies
- Appendicitis Diagnosis and Management
University of Cincinnati
2022-2025
University of Cincinnati Medical Center
2022-2025
Sabin Vaccine Institute
2023
The Ohio State University Wexner Medical Center
2017-2022
The Ohio State University
2018-2022
Ohio State University Hospital
2022
Harborview Medical Center
2016-2019
University of Washington
2010-2019
Seattle University
2016
University of Washington Medical Center
2013
Patients who are immunocompromised (IC) at increased risk of Clostridium difficile infection (CDI), which has to epidemic proportions over the past decade. Fecal microbiota transplantation (FMT) appears effective for treatment CDI, although there is concern that IC patients may be having adverse events (AEs) related FMT. This study describes multicenter experience FMT in patients.A retrospective series was performed on use with CDI recurrent, refractory, or severe. We aimed describe rates...
Guselkumab, a selective p19 interleukin-23 antagonist, is approved for the treatment of plaque psoriasis and psoriatic arthritis. This study evaluated efficacy safety guselkumab in patients with moderately to severely active Crohn's disease inadequate response or intolerance conventional biologic therapy.GALAXI-1, phase 2, double-blind, placebo-controlled study, randomized 1:1:1:1:1 intravenous 200 mg, 600 1200 mg at weeks 0, 4, 8; ustekinumab approximately 6 mg/kg week 0 90 subcutaneously...
Objective Anti–tumor necrosis factor (anti‐ TNF ) medications are effective in controlling chronic inflammatory diseases, but information about their use and safety pregnancy is limited. Consequently, anti‐ agents often discontinued early gestation. Certolizumab pegol ( CZP ), a PEG ylated, Fc‐free agent approved for the treatment of rheumatic diseases and/or Crohn's disease, has minimal to no active placental transfer. This analysis was undertaken evaluate outcomes women receiving ,...
Because of the ongoing epidemics obesity and diabetes, nonalcoholic steatohepatitis (NASH) may become a leading indication for liver transplantation. There are concerns about posttransplant survival patients with NASH because associated cardiovascular metabolic risk factors. We aimed to determine recent trends in proportion undergoing transplantation NASH-related cirrhosis United States estimate their survival. used data provided by Network Organ Sharing first-time adult cadaveric...
Abstract Background Inflammatory bowel diseases (IBD), including Crohn disease (CD) and ulcerative colitis (UC), are complex disorders with multiple comorbidities. We conducted international patient physician surveys to evaluate current experiences perceptions of patients CD or UC physicians who treat IBD. Methods The IBD Global Assessment Patient Physician Unmet Need Surveys comprised a survey survey, fielded in North America Europe between August 16, 2019, November 10, 2019. Adults...
We evaluated the real-world effectiveness and safety of ustekinumab (UST) in patients with Crohn's disease (CD).This study used a retrospective, multicenter, multinational consortium UST-treated CD patients. Data included patient demographics, phenotype, activity, treatment history, concomitant medications. Cumulative rates clinical, steroid-free, endoscopic, radiographic remissions were assessed using time-to-event analysis, clinical predictors by multivariate Cox proportional hazard...
Elevated serum uric acid (UA) levels strongly reflect and may even cause oxidative stress, insulin resistance, metabolic syndrome, which are risk factors for the progression of liver disease. We sought to determine whether UA associated with development cirrhosis or presence elevated enzymes. used cohort data from first National Health Nutrition Examination Survey (NHANES I) baseline level was incidence hospitalization death due among 5518 participants during a mean follow-up 12.9 years...
Introduction: Patients with ulcerative colitis (UC) and prior biologic failure may have reduced or delayed efficacy subsequent advanced therapies. This analysis evaluated the safety of ozanimod during True North (TN) study its open-label extension (OLE) in biologic-exposed patients UC. Methods: TN was a randomized, placebo-controlled 52-week trial (10-week induction, 42-week maintenance period). Eligible could enter OLE. Clinical outcomes were assessed at Week (W) 10 W52 OLE W46 W94....
Anti-tumor necrosis factors (anti-TNF) including infliximab, adalimumab and certolizumab pegol are used to treat Crohn's disease (CD) ulcerative colitis (UC). Paradoxically, while also indicated for the treatment of psoriasis, anti-TNF therapy has been associated with development psoriasiform lesions in IBD patients can compel discontinuation therapy. We aim investigate patient, clinical characteristics, frequency outcomes induced rash.We identify on anti-TNFs an onset a rash. Patient...
Ozanimod, an oral sphingosine 1-phosphate receptor modulator currently approved for the treatment of moderately to severely active ulcerative colitis and relapsing multiple sclerosis, showed clinical, endoscopic, histological benefit in phase 2 STEPSTONE trial Crohn's disease (CD). We aim describe design YELLOWSTONE 3 program evaluating safety efficacy ozanimod patients with CD.The consists 3, randomized, double-blind, placebo-controlled induction (NCT03440372 NCT03440385) maintenance...
The pivotal phase 3 True North (TN) study demonstrated the efficacy and safety of ozanimod in patients with moderately to severely active ulcerative colitis. This analysis assessed during TN ongoing open-label extension (OLE) disease who were naive advanced therapies (ATs).
Abstract Background Guselkumab (GUS) is a dual-acting IL-23 inhibitor that potently neutralizes and binds to CD64, receptor on cells produce IL-23. Induction with both intravenous (IV) subcutaneous (SC) GUS was effective in phase 2/3 clinical trials of participants (pts) moderately severely active Crohn’s disease (CD). To characterize the safety IV SC induction regimens, we evaluated data from CD. Methods We CD studies (GUS 200mg q4w GALAXI 1, 2, 3) 400mg SCq4w GRAVITI) assess rates events...
Abstract Background Guselkumab (GUS) is a dual-acting IL-23p19 subunit inhibitor that being evaluated in Crohn’s disease (CD). The GALAXI 1 study (NCT03466411) phase 2b GUS participants (pts) with moderately to severely active CD. Pts treated ustekinumab (UST) who met inadequate response criteria during long term extension (LTE) could cross over 200 mg q4w SC. Here, we present efficacy and safety results pts received after experiencing an UST the LTE. Methods Individuals prior or intolerance...
Abstract Background Guselkumab (GUS), a dual-acting IL-23 inhibitor that potently neutralizes and binds to CD64 (a receptor on cells produce IL-23), is currently approved in the United States for treatment of ulcerative colitis (UC) worldwide plaque psoriasis psoriatic arthritis. While GUS has been shown be safe Crohn’s disease (CD) UC, safety results have only reported individual trials date. To characterize overall profile inflammatory bowel (IBD), we evaluated pooled data from Phase 2/3...
Abstract Background Early biologic treatment is associated with better outcomes in pts CD. GALAXI 2 & 3 are identically designed trials assessing the efficacy and safety of guselkumab (GUS), a dual-acting IL-23p19 subunit inhibitor, moderately to severely active CD, BIO-naïve was previously reported.1,2,3 Here, we present results post-hoc analysis GUS disease duration ≤2yrs using data from pooled trials. Methods Pts had CD (based on CDAI SES-CD) history inadequate response/intolerance...
ABSTRACT Background Etrasimod is an oral, once‐daily (q.d.), selective sphingosine 1‐phosphate (S1P) 1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Unlike S1P ozanimod, etrasimod does not have a molecular structure inhibit monoamine oxidase (MAO). Coadministration drugs that MAO with opioids and antidepressants may increase risk adverse events (AEs). Aims This post hoc analysis evaluated incidence AEs potentially related serotonin...
Abstract Background GALAXI 1 is a Phase 2, double-blind, placebo (PBO)-controlled, multicenter study evaluating efficacy/safety of guselkumab (GUS), selective IL-23 p19 antagonist, in patients (pts) with moderately to severely active Crohn’s disease (CD) inadequate response/intolerance conventional therapies (corticosteroids, immunomodulators) and/or biologics (tumor necrosis factor antagonists, vedolizumab). At Week (Wk) 12, all GUS induction doses (200, 600, and 1200mg IV) had greater...
Abstract Background Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Using a novel electronic reporting tool, we aimed to prospectively describe onset tofacitinib efficacy during induction therapy in real-world study. Methods Patient-reported outcome data (PROs) including simple clinical activity index (SCCAI), PRO Measurement Identification Systems (PROMIS) measures, and adverse events were collected daily first 14 days at day 28 56. Paired...
Using Truven Health MarketScan Databases, we examined prescription opioid use in patients with inflammatory bowel disease (IBD) and the resultant increase of emergency services rise healthcare costs among these patients.